Abstract 206P
Background
The key roles of the TP53 mutation in cancer have been well established. However, the different biological processes of urothelial carcinoma (UC) stratified by the TP53 mutation status has not yet been described. Mutational signatures can reveal biological processes underlying carcinogenesis.
Methods
Patients diagnosed with UC were enrolled in the study. Tumor tissue and matching blood were sequenced by next-generation sequencing (NGS) techniques with Acornmed panel with 808 cancer-related genes.
Results
A total of 139 patients were enrolled including 69 patients with TP53 mutation and 70 patients with TP53 wildtype. In TP53 mutation cohorts, the five most frequently mutated genes were TP53 (100%), KMT2D (55%), RB1 (29%), KMT2C (26%), and FAT1 (25%). For TP53 wildtype cohorts, the five most frequently mutated genes were KMT2D (43%), FGFR3 (30%), FAT1 (28%), BRD4 (26%), and KMT2C (25%). For top 20 gene, 4 frequently mutated genes were significant difference between TP53 mutation and TP53 wildtype cohorts, such as ERBB3, FGFR3, ERCC2, and STAG2, excluding the TP53 gene. C to T (C>T) substitutions and transitions were dominant mutation types in both cohorts (39.8% and 44.0%, 50% and 55%, respectively). APOBEC Cytidine Deaminase (Signature 2) were shown in both cohorts. Surprising, exposure to aristolochic acid (Signature 22) and defective DNA mismatch repair (Signature 6) were only existed in TP53 mutation cohorts, whereas spontaneous deamination of 5−methylcytosine (Signature 1) and defects in polymerase POLE (Signature 10) were only discovered in TP53 wildtype cohorts.
Conclusions
There were characterized the genomic differences and similarities, stratified by the TP53 status, which may reflect the UC patients with TP53 mutation harbored a specific biological process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H.H. Liu, X.Y. Liang, L.B. Chen, Y. Zhang, H.N. Wang, F. Lou, S. Cao: Full/Part-time employment: Beijing Acornmed Biotechnology Co., Ltd.
Resources from the same session
24P - The Pink Vans: Bringing cancer screening closer to home
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
25P - Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Presenter: Alexander Sultanbaev
Session: e-Poster Display Session
26P - Body mass index and clinical outcomes in Egyptian women with breast cancer: A multi-institutional study
Presenter: Amrou Mamdouh Abdeen Shaaban
Session: e-Poster Display Session
27P - Breast cancer primary site and laterality as predictive factors of prognosis: SEER based analysis for survival
Presenter: Eman Zin Eldin
Session: e-Poster Display Session
28P - Breast cancer care services at Nilai Medical Centre: A Malaysian experience
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
29P - Factors affecting breast self-examination (BSE) behaviour among female high school students in Denpasar City, Bali
Presenter: Cindy Trisina
Session: e-Poster Display Session
30P - Male breast cancer: A rural based peripheral cancer center experience
Presenter: SACHIN KHANDELWAL
Session: e-Poster Display Session
31P - The prognostic value of pre-treatment peripheral neutrophil-lymphocyte-ratio (NLR) and its correlation with mutant p53 expression in Indonesian triple negative breast cancer patients
Presenter: Rosita Purwanto
Session: e-Poster Display Session
32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
Presenter: Izzet Dogan
Session: e-Poster Display Session
33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting
Presenter: Krithikaa Sekar
Session: e-Poster Display Session